Surveillance of Acutely Ill Adults with Respiratory Viruses, including SARS-CoV-2

CDC awarded contract 75D30122C14944 to Vanderbilt University Medical Center, 1161 21st Ave S STE D3300 MCN, Nashville, TN 37232 on 30 August 2022, in the amount of $49,995,944.00.

This contract provides a contractor-coordinated observational, multicenter, health surveillance network of no fewer than fifteen (15) and no more than thirty (30) nationally recognized healthcare facilities (hospitals, medical centers, universities) to conduct surveillance of COVID-19, influenza, and respiratory syncytial virus (RSV) among patients hospitalized with acute respiratory illness (ARI).  The primary objective of this effort is evaluating and monitoring vaccine effectiveness (VE) against COVID-19 and influenza-associated hospitalizations. As respiratory syncytial virus (RSV) vaccines become available, the network will also evaluate and monitor VE against RSV-associated hospitalizations. Vaccine effectiveness estimates will include effectiveness against emerging variants of concern and duration of protection. These efforts will help CDC understand vaccine failures, severe ARI, severity scores, susceptibility to infection, and mechanisms of disease attenuation. Work also includes evaluating potential therapeutics on outcomes such as ICU admission, length of hospital stay, and death resulting from COVID-19, RSV and influenza.

The period of performance is for a 1-year base period from 1 September 2022 through 31 August 2023 followed by 2 1-year option periods.

Awarded contract 75D30122C14944 to Vanderbilt University Medical Center for 49995944.00 on 2022-08-30.